RPRX - Royalty Pharma plc
About Royalty Pharma plc (https://www.royaltypharma.com)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | 1963 | $44,019,342 USD |
| James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer | 1971 | $3,395,000 USD |
| Christopher Hite | Chairman of Partnering & Investments | 1968 | $1,323,000 USD |
| Marshall Urist | Executive Vice President of Research & Investments | 1977 | $1,323,000 USD |
| Terrance Coyne | Executive Vice President & Chief Financial Officer | – | $1,323,000 USD |
| Arthur Richard McGivern | Executive VP & Chief Legal Officer | 1975 | – |
| Ashwin Pai | Executive Vice President of Investments & Partnering | – | – |
| Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer | – | – |
| George Grofik | Senior Vice President and Head of Investor Relations & Communications | – | – |
| Molly Sawaya | Executive Vice President & Head of Human Capital | – | – |
| Sandy Balkin | Senior Vice President of Strategy & Analytics | – | – |